Clinical and pharmacokinetic phase II study of one hour infusion of kahalalide F administered every week to patients with Non Small Cell Lung Cancer Stage IIIB with pleural effusion and stage IV, after first line chemotherapy
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Kahalalide F (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors PharmaMar
Most Recent Events
- 13 Apr 2022 New trial record